By Katherine Hamilton

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences.

Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn't expect the trial to yield positive results. It also ended a phase 2 study.

Gilead's option rights to certain early pipeline programs under its 2020 agreement with Arcus will end in July due to Gilead's decision to not make the option continuation payment to Arcus.

Gilead won't have option rights to additional Arcus programs, but will maintain its existing time-limited options.

The decision is based on the recommendation of the Independent Data Monitoring Committee, following its review of data from a pre-planned futility analysis.

The analysis didn't assess safety, but no new safety issues were identified during regular reviews.

Gilead is communicating with investigators to determine appropriate next steps for patients in the studies.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 20, 2026 08:47 ET (12:47 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.